In TCGA database, patients with LRP1B mutation have no benefits on conventional chemotherapy in melanoma and NSCLC (Supplementary Figure 9), but displayed preferable clinical outcome in immune check-point blockades therapy, suggested the molecular marker prediction of selectivity and specificity in drug treatment. This evidence concerns the gene LRP1B and non-small cell lung carcinoma.